You are here:

ondansetron (Setofilm)

Advice

following an abbreviated submission

ondansetron orodispersible films (Setofilm®) are accepted for restricted use within NHS Scotland.

Indication under review:
In adults:

  • Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy.
  • Prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy.
  • Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy.
  • Prophylaxis and treatment of post-operative nausea and vomiting (PONV).

In paediatric populations:

  • Management of chemotherapy-induced nausea and vomiting in children aged  ≥6 months.
  • Prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged  ≥4 years.

SMC restriction: ondansetron orodispersible films are restricted to use in patients with an enhanced risk of aspiration or who experience difficulties in swallowing.

Generic preparations of ondansetron are available at a lower cost than the proprietary products.

Drug Details

Drug Name: ondansetron (Setofilm)
SMC Drug ID: 912/13
Manufacturer: Norgine Ltd
Indication: In adults: • Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy. • Prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy. • Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy. • Prophylaxis and treatment of post-operative nausea and vomiting (PONV). In paediatric populations: • Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months. • Prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years.
BNF Category:
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 11 November 2013

Back